CAJ | 학술논문

目的：观察小剂量茶碱缓释片联合沙美特罗替卡松粉吸入剂治疗慢性阻塞性肺疾病（ COPD）的疗效和安全性。方法将99例中重度稳定期COPD患者随机分为2组。治疗组50例应用小剂量茶碱缓释片＋沙美特罗替卡松粉吸入剂50/250μg，对照组49例应用沙美特罗替卡松粉吸入剂50/500μg，治疗6个月。观察2组治疗前后肺功能指标变化、慢性阻塞性肺病评估测试（ CAT）评分变化、诱导痰中性粒细胞计数变化。肺功能指标包括第1 s用力呼气容积（ FEV1）占预计值百分比（ FEV1％）、FEV1/用力肺活量（ FVC）、深吸气量（ IC）占预计值百分比（ IC％）。结果2组治疗后FEV1％、IC％均较本组治疗前明显升高（ P＜0．05），CAT评分降低（P＜0．05），诱导痰中性粒细胞计数降低（P＜0．05）。结论小剂量茶碱缓释片联合沙美特罗替卡松粉吸入剂治疗中重度稳定期COPD安全有效。
목적：관찰소제량다감완석편연합사미특라체잡송분흡입제치료만성조새성폐질병（ COPD）적료효화안전성。방법장99례중중도은정기COPD환자수궤분위2조。치료조50례응용소제량다감완석편＋사미특라체잡송분흡입제50/250μg，대조조49례응용사미특라체잡송분흡입제50/500μg，치료6개월。관찰2조치료전후폐공능지표변화、만성조새성폐병평고측시（ CAT）평분변화、유도담중성립세포계수변화。폐공능지표포괄제1 s용력호기용적（ FEV1）점예계치백분비（ FEV1％）、FEV1/용력폐활량（ FVC）、심흡기량（ IC）점예계치백분비（ IC％）。결과2조치료후FEV1％、IC％균교본조치료전명현승고（ P＜0．05），CAT평분강저（P＜0．05），유도담중성립세포계수강저（P＜0．05）。결론소제량다감완석편연합사미특라체잡송분흡입제치료중중도은정기COPD안전유효。
Objective To evaluate the effect and its side effects of low-dose theophylline plus salmeterol fluticasone 50/250 μg combination therapy in patients with moderate to severe stable chronic obstructive pulmonary disease( COPD) .Methods 99 patients with moderate to severe stable COPD were divided into low-dose theophyl-line plus salmeterol fluticasone 50/250 μg group and salmeterol fluticasone 50/500 μg group.After 6 months treat-ment two groups were compared in respiratory function ( including FEV1%, FEV1/FVC,IC and IC %) , COPD as-sessment test ( CAT ) score, induced sputum neutrophil counts and adverse events.Results FEV1/FVC and FEV1%after treatment were increased in two groups ( P <0.05).There was no difference between two groups on FEV1/FVC and FEV1%( P >0.05).CAT scores after treatment (21.88 ±8.14) was decreased as compared with that before treatment (26.50 ±6.62, P <0.05) in treatment group.CAT scores after treatment (22.40 ±7.83) was decreased as compared with that before treatment (26.01 ±7.89, P <0.05) in control group.The induced sputum neutrophil counts:before and after the treatment the two groups'induced sputum neutrophil counts difference were sta-tistically significant ( P <0.05), the difference between groups showed no statistical significance ( P >0.05);Conclusion Low-dose theophylline combined salmeterol fluticasone 50/250 μg treatment is safe and effective in stable chronic obstructive pulmonary disease patients.